2023
Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Nagarajan P, Maronge J, Johnson J, Rosenthal D, Myers J, Gross N. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology - Head & Neck Surgery 2023, 149: 847-849. PMID: 37535378, PMCID: PMC10401391, DOI: 10.1001/jamaoto.2023.1729.Peer-Reviewed Original ResearchImmuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.
Ferrarotto R, Johnson F, Hutcheson K, Sui D, Johnson J, Ebersole B, Mott F, Lewis C, Bonini F, Hoff C, Mitani Y, Cortez M, Bell D, El-Naggar A, Gunn G, Fuller C, Myers J, Lee J, Rosenthal D, Diaz E. Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results. Journal Of Clinical Oncology 2023, 41: 6008-6008. DOI: 10.1200/jco.2023.41.16_suppl.6008.Peer-Reviewed Original ResearchTreatment-related adverse eventsPathologic complete responseLarynx squamous cell carcinomaCo-primary endpointsEarly recurrenceCommon treatment-related adverse eventsStage IIDisease control rateLaryngeal preservation rateSolitary lung metastasisRelapse-free survivalSquamous cell carcinomaLoss of insuranceSingle treatment modalityAUC 6Eligible ptsEvaluable patientsImmuno-chemotherapyLarynx biopsiesDefinitive radiotherapyEfficacy endpointPrimary endpointRECIST 1.1Secondary endpointsAdverse events
2022
Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study
Ng S, Cardenas C, Bahig H, Elgohari B, Wang J, Johnson J, Moreno A, Shah S, Garden A, Phan J, Gunn G, Frank S, Ding Y, Na L, Yuan Y, Urbauer D, Mohamed A, Rosenthal D, Morrison W, MacManus M, Fuller C. Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study. Current Oncology 2022, 29: 6303-6313. PMID: 36135064, PMCID: PMC9498049, DOI: 10.3390/curroncol29090495.Peer-Reviewed Original ResearchConceptsApparent diffusion coefficientPost-treatment MRIT3-T4 tumorsIntact primary tumorSquamous cell carcinomaT1-T2 tumorsDifferent treatment responsesNodal diseaseOropharyngeal cancerClinical featuresSpearman correlation coefficientCell carcinomaNeck cancerPrimary tumorNeck radiotherapyNodal sitesTreatment responseWeek 4Weekly MRIPatientsMR biomarkersGTV sizeNodal volumeADC valuesTumorsLong-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN).
Gross N, Ferrarotto R, Amit M, Nagarajan P, Yuan Y, Bell D, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Wargo J, Weber R, Myers J. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Journal Of Clinical Oncology 2022, 40: 9519-9519. DOI: 10.1200/jco.2022.40.16_suppl.9519.Peer-Reviewed Original ResearchPathologic complete responseOverall response rateCutaneous squamous cell carcinomaPhase II trialPathologic responseLong-term outcomesNeoadjuvant immunotherapySquamous cell carcinomaAdverse eventsCSCC-HNII trialCell carcinomaGrade 2 adverse eventsPilot phase II trialGrade 3 diarrheaMajor pathologic responsePathologic partial responseAdjuvant radiation therapyWarrants further investigationMedian followRECIST v1.1Adjuvant radiationPrimary endpointRecurrent diseaseSecondary endpoints
2020
Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study.
Gunn G, Ferrarotto R, Johnson F, Bell D, Cardoso R, Johnson J, Rubin M, Yuan Y, Frank S, Fuller C, Rosenthal D, Kupferman M, Goepfert R, Hessel A, Hutcheson K, Gross N. Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study. Journal Of Clinical Oncology 2020, 38: 6578-6578. DOI: 10.1200/jco.2020.38.15_suppl.6578.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaTransoral robotic surgeryIntensity-modulated proton therapySquamous cell carcinomaKcal/dayOverall cohortCell carcinomaFunctional outcomeMedian age 59 yearsSubjective patient-reported outcome measuresPatient-reported outcome measuresActiGraph accelerometer dataParallel cohort studyAge 59 yearsDe-escalation trialsObjective functional outcomesSingle modality treatmentTime of presentationUntreated stage ISignificant decreaseVigorous physical activitySteps/minuteLong-term toxicityCohort studyExcellent prognosis
2018
Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer
Ng S, Johnson J, Gunn G, Rosenthal D, Skinner H, Phan J, Frank S, Morrison W, Sturgis E, Mott F, Williams M, Fuller C, Garden A. Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: 1029-1035. PMID: 29960060, PMCID: PMC9620951, DOI: 10.1016/j.ijrobp.2018.06.031.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaComplete metabolic responseDisease-free survivalOverall survival rateSquamous cell carcinomaCell carcinomaTomography scanSurvival rateHPV-positive oropharyngeal cancerCommon primary siteHPV/p16Posttreatment PET imagingPosttreatment PET scansKaplan-Meier methodSubgroup of patientsBase of tongueGroup of patientsHuman papilloma virusDevelopment of recurrencePET/CT imagingMetabolic responseOptimal surveillance strategyPositron emission tomographyLonger life expectancyEleven patients
2017
Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx
Shiao J, Mohamed A, Messer J, Hutcheson K, Johnson J, Enderling H, Kamal M, Warren B, Pham B, Morrison W, Zafereo M, Hessel A, Lai S, Kies M, Ferrarotto R, Garden A, Schomer D, Gunn G, Phan J, Frank S, Beadle B, Weber R, Lewin J, Rosenthal D, Fuller C. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head & Neck 2017, 39: 1609-1620. PMID: 28464542, PMCID: PMC5511768, DOI: 10.1002/hed.24804.Peer-Reviewed Original ResearchConceptsT4a laryngeal cancerSquamous cell carcinomaTumor volumeOverall survivalLaryngeal cancerFive-year overall survivalWorse disease-specific survivalLaryngeal squamous cell carcinomaFive-year OSCause-specific survivalDisease-specific survivalEvent-free survivalIndependent prognostic factorRecurrence-free survivalPrimary tumor volumeSignificant independent correlatesTumor volume measurementsLarynx preservationOncologic outcomesPrognostic factorsPretreatment CTSquamous carcinomaCell carcinomaIndependent correlatesTotal laryngectomy